➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Baxter
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Litigation Details for Belcher Pharmaceuticals, LLC v. Hospira, Inc. (D. Del. 2017)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Belcher Pharmaceuticals, LLC v. Hospira, Inc. (D. Del. 2017)

Docket   Start Trial Date Filed 2017-06-19
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand None Referred To
Parties BELCHER PHARMACEUTICALS, LLC; HOSPIRA, INC.
Patents 10,352,943; 6,827,946; 6,858,580; 7,264,933; 7,438,909; 7,722,909; 7,763,256; 7,933,722; 7,989,205; 7,994,214; 7,994,223; 7,994,364; 8,889,616; 8,889,831; 8,933,191; 8,969,384; 8,969,398; 9,283,197; 9,730,943; 9,730,946; 9,763,933; 9,775,946; 9,943,485; 9,943,601; 9,943,649; 9,994,174; 9,994,858
Attorneys Chaz L. Enerio; Cole Y. Carlson; David A. Bilson; Devon W. Edwards; Heather M. Schneider; J. Clayton Athey; John C. Phillips , Jr.; Matthew Freimuth; Megan C. Haney; Sara E. Bussiere; Stefan V. Stein; Stephen B. Brauerman; Thomas J. Meloro
Firms Bayard, P.A.; Phillips, Goldman, McLaughlin & Hall, P.A.; Prickett, Jones & Elliott, P.A.
Link to Docket External link to docket
Small Molecule Drugs cited in Belcher Pharmaceuticals, LLC v. Hospira, Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Belcher Pharmaceuticals, LLC v. Hospira, Inc. (D. Del. 2017)

Date Filed Document No. Description Snippet Link To Document
2020-03-31 244 Opinion -for material to the patentability of the ’197 Patent. (Pinal Tr. at 230-31, 352-53) B. … ’197 Patent lists Jugal K. Taneja as the sole inventor. (SF ¶ 4; see also JTX-1) 10. The… substantial, ten-fold difference between the concentration claimed in the ’197 Patent (1.0-1.06 mg/mL…and 7 of the ’197 Patent under the doctrine of equivalents (“DOE”). (D.I. 222 at 5-10) Belcher has failed…substantially (i.e., ten-fold) below. (JTX-2 at 66; D.I. 232 at 6; FF ¶ 59) Throughout the entire Patent, that range External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Express Scripts
Boehringer Ingelheim
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.